2137 — Brii Biosciences Income Statement
0.000.00%
Last trade - 00:00
- HK$1.01bn
- -HK$1.91bn
- CNY0.62m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0 | 51.6 | 0.617 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 520 | 1,282 | 4,190 | 541 | 184 |
Operating Profit | -520 | -1,282 | -4,190 | -489 | -184 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -521 | -1,284 | -4,191 | -490 | -184 |
Provision for Income Taxes | |||||
Net Income After Taxes | -521 | -1,284 | -4,191 | -490 | -184 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -521 | -1,190 | -4,164 | -484 | -175 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -521 | -1,190 | -4,164 | -484 | -175 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.738 | -1.66 | -9.41 | -0.669 | -0.414 |
Dividends per Share |